A Prospective, Multi-Center, Pivotal Study to Evaluate the Safety and Effectiveness of the NovaCross™ Micro-catheter in Facilitating Crossing Chronic Total Occlusion (CTO) Coronary Lesions

Completed · Not applicable

Conditions studied: Chronic Total Occlusion of Coronary Artery

In brief

This study evaluates the safety and effectiveness of the a novel device called NovaCross to help cross Chronic Total Occlusion (CTO) lesions in coronary arteries.

Key facts

Study ID: NCT02477579
Run by: Nitiloop Ltd.
People needed: 145
Starts: 2015-05-17
Expected to finish: 2017-08-10
Last updated by the study team: 2017-08-17

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Adult aged 25-80
Patient understands and has signed the study informed consent form.
Patient has an angiographic documented Chronic Total Occlusion (i.e. >3 months occlusion duration) showing distal TIMI flow 0.
Suitable candidate for non-emergent, coronary angioplasty
Documented coronary angiography preceding the PCI reveals at least one CTO lesion situated in a non-infarct related coronary artery or its side branches
Body Mass Index (BMI) < 40
Left ventricle ejection fraction > 25%

You may not qualify if…

Patient unable to give informed consent.
Current participation in another study with any investigational drug or device.
Patient is known or suspected not to tolerate the contrast agent.
Aorta-ostial CTO location (Ostial bifurcation origins may be considered), SVG CTO, in-stent CTO.
Intolerance to Aspirin and/or inability to tolerate a second antiplatelet agent (Clopidogrel and Prasugrel and Ticagrelor).
Appearance of a fresh thrombus or intraluminal filling defects.
Recent major cerebrovascular event (history of stroke or TIA within 1 month)
Cardiac intervention within 4 weeks of the procedure
Renal insufficiency (serum creatinine of > 2.3mg/dl or 203μmol/L)
Active gastrointestinal bleeding
Active infection or fever that may be due to infection
Life expectancy < 2 years due to other illnesses
Significant anemia (hemoglobin < 8.0 mg / dl)
Severe uncontrolled systemic hypertension (> 240 mmHg within 1 month of procedure)
Severe electrolyte imbalance
Congestive heart failure [New York Heart Association (NYHA) Class III\\IV] CSA Class IV.
Unstable angina requiring emergent percutaneous trans-luminal coronary angioplasty (PTCA) or coronary artery bypass graft (CABG)
Recent myocardial infarction (MI) (within the past two weeks)
Uncontrolled diabetes >2 serum glucose concentrations of >350 mg/dl within 7 days.
Unwillingness or inability to comply with any protocol requirements
Pregnant or nursing
Extensive prior dissection from a coronary guidewire use
Drug abuse or alcoholism.
Patients under custodial care.
Bleeding diathesis or coagulation disorder;

Where it is running

Central Arkansas Veterans Healthcare System — Little Rock, Arkansas, United States
Edward Hospital — Naperville, Illinois, United States
Columbia University Medical Center/New York Presbyterian Hospital — New York, New York, United States
York Hospital — York, Pennsylvania, United States
SPZOZ University Hospital in Krakow — Krakow, Poland

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.